WHAT IS CLAIMED:

1. A compound of formula **I**:



I

or a pharmaceutically acceptable salt, hydrate, solvate or a mixture thereof, wherein:

(a) each occurrence of m is independently an integer ranging from 0 to 5;

(b) each occurrence of n is independently an integer ranging from 3 to 7;

(c) X is $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4;

(d) each occurrence of R^1 and R^2 is independently $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(e) each occurrence of R^{11} and R^{12} and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(f) each occurrence of Y^1 and Y^2 is independently $(C_1–C_6)$alkyl, OH, COOH, $COOR^3$, SO_3H,





wherein:

(i) R^3 is $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1–C_6)$alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, or $(C_2–C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $C_1–C_6$ alkoxy, or phenyl groups; and

(iii) each occurrence of R^5 is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, or $(C_2–C_6)$alkynyl.

2. The compound of claim 1, wherein each occurrence of Y^1 and Y^2 is independently OH, $COOR^3$, or COOH.

3. The compound of claim 1, wherein m is 0.

4. The compound of claim 1, wherein m is 1.

5. The compound of claim 1, wherein n is 4.

6. The compound of claim 1, wherein n is 5.

7. The compound of claim 1, wherein X is $(CH_2)_z$ and z is 0.

8. The compound of claim 1, wherein each occurrence of R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group.

9. The compound of claim 1, wherein Y^1 and Y^2 are each independently $(C_1$–$C_6)$alkyl.

10. The compound of claim 1, wherein Y^1 and Y^2 are each methyl.

11. A compound of the formula **II**:



II

or a pharmaceutically acceptable salt, hydrate, solvate, or mixtures thereof, wherein

(a) each occurrence of R^1 and R^2 is independently $(C_1$–$C_6)$alkyl, $(C_2$–$C_6)$alkenyl, $(C_2$–$C_6)$alkynyl, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(b) each occurrence of R^{11} and R^{12} and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(c) each occurrence of n is independently an integer ranging from 1 to 7;

(d) X is $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4;

(e) each occurrence of m is independently an integer ranging from 0 to 4;

(f) each occurrence of Y^1 and Y^2 is independently $(C_1$–$C_6)$alkyl, CH_2OH, C(O)OH, $OC(O)R^3$, $C(O)OR^3$, SO_3H,

24. The compound of claim 11, wherein C^{*1} C^{*2} are of the stereochemical configuration (S^1,S^2) or substantially (S^1,S^2).

25. The compound of claim 11, wherein C^{*1} C^{*2} are of the stereochemical configuration (S^1,R^2) or substantially (S^1,R^2).

26. The compound of claim 11, wherein C^{*1} C^{*2} are of the stereochemical configuration (R^1,R^2) or substantially (R^1,R^2).

27. The compound of claim 11, wherein C^{*1} C^{*2} are of the stereochemical configuration (R^1,S^2) or substantially (R^1,S^2).

28. A compound of formula **III**:



III

or a pharmaceutically acceptable salt, hydrate, solvate, or mixtures thereof, wherein:

(a) each occurrence of R^1 and R^2 is independently (C_1–C_6)alkyl, (C_2–C_6)alkenyl, (C_2–C_6)alkynyl, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a (C_3-C_7)cycloakyl group;

(b) each occurrence of R^{11} and R^{12} and the carbon to which they are both attached are taken together to form a (C_3-C_7)cycloakyl group;

(c) each occurrence of n is independently an integer ranging from 1 to 7;

(d) X is $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4;

(e) each occurrence of m is independently an integer ranging from 0 to 4;

(f) each occurrence of Y^1 and Y^2 is independently (C_1–C_6)alkyl, CH_2OH, C(O)OH, $OC(O)R^3$, $C(O)OR^3$, SO_3H,



wherein:

(i) R^3 is $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1–C_6)$alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, or $(C_2–C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $C_1–C_6$ alkoxy, or phenyl groups;

(iii) each occurrence of R^5 is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, or $(C_2–C_6)$alkynyl; and

(f) each occurrence of b is independently 0 or 1 or optionally the presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds.

29. A compounds of formula **IV**:



IV

or a pharmaceutically acceptable salt, hydrate, solvate, or mixture thereof, wherein

(a) each occurrence of R^1 and R^2 is independently $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(b) each occurrence of R^{11} and R^{12} and the carbon to which they are both attached are taken together to form a $(C_3$-$C_7)$cycloakyl group;

(c) each occurrence of n is independently an integer ranging from 1 to 7;

(d) X is $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4;

(e) each occurrence of m is independently an integer ranging from 0 to 4;

(f) each occurrence of Y^1 and Y^2 is independently $(C_1–C_6)$alkyl, CH_2OH, C(O)OH, $OC(O)R^3$, $C(O)OR^3$, SO_3H,





wherein:

(i) R^3 is $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1–C_6)$alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, or $(C_2–C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $C_1–C_6$ alkoxy, or phenyl groups;

(iii) each occurrence of R^5 is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, or $(C_2–C_6)$alkynyl; and

(g) b is 0 or 1 or optionally the presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds.

30. A compound of formula **V**:



V

or a pharmaceutically acceptable salt, hydrate, solvate, or mixture thereof, wherein

(a) each occurrence of R^1 and R^2 is independently $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3\text{-}C_7)$cycloakyl group;

(b) each occurrence of R^{11} and R^{12} and the carbon to which they are both attached are taken together to form a $(C_3\text{-}C_7)$cycloakyl group;

(c) each occurrence of n is independently an integer ranging from 1 to 7;

(d) X is $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4;

(e) each occurrence of m is independently an integer ranging from 0 to 4; and

(f) each occurrence of Y^1 and Y^2 is independently $(C_1–C_6)$alkyl, CH_2OH, C(O)OH, $OC(O)R^3$, $C(O)OR^3$, SO_3H,





wherein:

(i) R^3 is $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1–C_6)$alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, or $(C_2–C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $C_1–C_6$ alkoxy, or phenyl groups; and

(iii) each occurrence of R^5 is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, or $(C_2–C_6)$alkynyl.

31. A compound of structure:













32. A pharmaceutical composition comprising a compound of claim 1, 11, 28, 29, 30, or 31 and a pharmaceutically acceptable vehicle, excipient, or diluent.

33. The pharmaceutical composition comprising a compound of claim 1, 11, 28, 29, 30, or 31 further comprising a second therapeutic agent.

34. A method for treating or preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder, modulating C reactive protein, or enhancing bile production in a

patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or proplyleutrally effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

35. A method for treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

36. A method for treating or preventing a dyslipidemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically, effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

37. A method for treating or preventing a dyslipoproteinemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

38. A method for treating or preventing a disorder of glucose metabolism in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

39. A method for treating or preventing Alzheimer's disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

40. A method for treating or preventing Syndrome X in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

41. A method for treating or preventing septicemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

42. A method for treating or preventing a thrombotic disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

43. A method for treating or preventing a peroxisome proliferator activated receptor associated disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

44. A method for treating or preventing obesity in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

45. A method for treating or preventing pancreatitis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

46. A method for treating or preventing hypertension in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

47. A method for treating or preventing renal disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

48. A method for treating or preventing cancer in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

49. A method for treating or preventing inflammation in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

50. A method for treating or preventing impotence in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

51. A method for treating or preventing a neurodegenerative disease or disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

52. A method of inhibiting fatty acid synthesis in a patient, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

53. A method inhibiting sterol synthesis in a patient, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

54. A method of treating or preventing a metabolic syndrome disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

55. A pharmaceutical composition comprising a compound of claim 1, 11, 28, 29, 30, or 31 and a pharmaceutically acceptable vehicle, excipient, or diluent which is administered in combination with a statin.

56. A method of treating or preventing a disease or disorder that is capable of being treated or prevented by increasing HDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.

57. A method of treating or preventing a disease or disorder that is capable of being treated or prevented by decreasing LDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 11, 28, 29, 30, or 31.



wherein:

(i) R^3 is $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, $(C_2–C_6)$alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, $(C_1–C_6)$alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, $(C_1–C_6)$alkyl, $(C_2–C_6)$alkenyl, or $(C_2–C_6)$alkynyl and is unsubstituted or substituted with one or two halo, OH, $C_1–C_6$ alkoxy, or phenyl groups;

(iii) each occurrence of R^5 is independently H, (C_1–C_6)alkyl, (C_2–C_6)alkenyl, or (C_2–C_6)alkynyl; and

(g) b is 0 or 1 or optionally the presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds.

12. The compound of claim 11, wherein each occurrence of Y^1 and Y^2 is independently OH, $COOR^7$, or COOH.

13. The compound of claim 11, wherein m is 4.

14. The compound of claim 11, wherein m is 5.

15. The compound of claim 11, wherein X is $(CH_2)_z$ and z is 0.

16. The compound of claim 11, wherein each occurrence of R^1 and R^2 and the carbon to which they are both attached are taken together to form a (C_3-C_7)cycloakyl group.

17. The compound of claim 11, wherein Y^1 and Y^2 is C(O)OH or CH_2OH.

18. The compound of claim 11, wherein R^3 and R^4 are each independently (C_1–C_6) alkyl.

19. The compound of claim 11, wherein R^3 and R^4 are each methyl.

20. The compound of claim 11, wherein C^{*1} is of the stereochemical configuration R or substantially R.

21. The compound of claim 11, wherein C^{*1} is of the stereochemical configuration S or substantially S.

22. The compound of claim 11, wherein C^{*2} is of the stereochemical configuration R or substantially R.

23. The compound of claim 11, wherein C^{*2} is of the stereochemical configuration S or substantially S.